ClinicalTrials.gg
CompletedNCT00701558Updated Jun 24, 2016Results posted

A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer

A Phase 2 interventional study of Erlotinib and Gemcitabine in Non-small Cell Lung Cancer Metastatic, sponsored by Hoffmann-La Roche. Completed at 1 site in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-24.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 5 under way, 2 of them phase 3. erlotinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
167th of 200
20 · median 58
Started
2008
with 22 others
Phase 2
120 of 203
none open now
Registered
96th of 203
by date
Lead sponsor
28 of 203
Hoffmann-La Roche

Among the 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung, this one is the 167th largest by enrollment of the 200 interventional ones that give a count, is one of 23 that started in 2008, is one of 120 in phase 2, and was the 96th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About erlotinib

erlotinib: first FDA approval 2004 (TARCEVA), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This single arm study will assess the efficacy and safety of erlotinib + gemcitabine in chemotherapy-naive participants with unresectable, advanced and/or metastatic non-small cell lung cancer. Participants will receive erlotinib 150 mg orally (po) daily, in combination with gemcitabine 1000 mg/m\^2 intravenously (iv) weekly for 3 weeks of each 4 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.

03

Conditions studied

  • Non-small Cell Lung Cancer Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • advanced and/or (stage IIIB/IV) unresectable non-small cell lung cancer;
  • no previous systemic chemotherapy, radiation therapy or immunotherapy;
  • (ECOG) >=2.

Exclusion criteria

Exclusion Criteria:

  • prior systemic anti-tumor therapy with human epidermal growth factor receptor 1 (HER1/EGFR) inhibitors;
  • active, non-controlled systemic disease;
  • any other within 5 years (except for adequately treated cancer in situ of cervix, or basal or squamous cell skin cancer).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Erlotinib + Gemcitabine

    Participants received erlotinib 150 mg/day, orally (po) on a continuous schedule in combination with gemcitabine at 1000 mg/m\^2 administered intravenously (iv) on days 1, 8, 15 of each 4 week cycle for 6 cycles as per standard medical care, or until disease progression or participant's withdrawal due to any reason or death.

    Drug: Erlotinib · Drug: Gemcitabine

Interventions

  • 150 mg po daily

    Also known as: Tarceva

  • 1000 mg/m\^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles

06

What researchers measure

Primary outcomes

  1. Time to Disease Progression

    Time to disease progression or progression free survival (PFS) was defined as the interval between the day of randomization and the date of the first documentation of disease progression or date of death (from any cause), whichever occurs first.

    Time frame: From the time of randomization until disease progression or death (up to 193 weeks)]

  2. Overall Response Rate (ORR)

    Overall response rate was defined as the percentage of participants who had any evidence of confirmed objective complete response (CR) or partial response (PR), per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) and assessed by computed tomography imaging (CT): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: From the time of randomization until disease progression or death (up to 193 weeks)

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the interval between the day of randomization and the date of death from any cause.

    Time frame: From the time of randomization until death (up to 193 weeks)

07

Results

Posted May 19, 2016

Participant flow

Participant flow — Overall Study
MilestoneErlotinib + Gemcitabine
Started19
Completed4
Not completed15
Withdrew: Death7
Withdrew: Lost to follow-up8

Outcome measures

PrimaryTime to Disease Progression

Time to disease progression or progression free survival (PFS) was defined as the interval between the day of randomization and the date of the first documentation of disease progression or date of death (from any cause), whichever occurs first.

Time frame:
From the time of randomization until disease progression or death (up to 193 weeks)]
Reported as:
Median · weeks
Time to Disease Progression
weeksErlotinib + Gemcitabine
Time to Disease Progression15 (7 to 36)
PrimaryOverall Response Rate (ORR)

Overall response rate was defined as the percentage of participants who had any evidence of confirmed objective complete response (CR) or partial response (PR), per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) and assessed by computed tomography imaging (CT): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
From the time of randomization until disease progression or death (up to 193 weeks)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsErlotinib + Gemcitabine
Overall Response Rate (ORR)15.8
SecondaryOverall Survival

Overall survival was defined as the interval between the day of randomization and the date of death from any cause.

Time frame:
From the time of randomization until death (up to 193 weeks)
Reported as:
Median · weeks
Overall Survival
weeksErlotinib + Gemcitabine
Overall Survival39 (27 to 51)

Adverse events

Collected over Up to 28 days after last study drug administration in the study treatment phase (up to 197 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Erlotinib + Gemcitabine—2/19 (10.5%)15/19 (78.9%)
Most frequent serious events
Most frequent serious events
EventErlotinib + Gemcitabine
DiarrhoeaGastrointestinal disorders1/19
Respiratory tract infectionRespiratory, thoracic and mediastinal disorders1/19
Most frequent other events
Most frequent other events
EventErlotinib + Gemcitabine
Anaemia of malignant diseaseBlood and lymphatic system disorders7/19
ThrombocytopeniaBlood and lymphatic system disorders6/19
RashSkin and subcutaneous tissue disorders3/19
NeutropeniaBlood and lymphatic system disorders2/19
DiarrhoeaGastrointestinal disorders2/19
Blood bilirubin increasedInvestigations2/19
LeukopeniaBlood and lymphatic system disorders1/19
FatigueGeneral disorders1/19
Appetite lostMetabolism and nutrition disorders1/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)Erlotinib + Gemcitabine
Mean62.47 ± 9.67
Sex: Female, Male
Sex: Female, Male(Participants)Erlotinib + Gemcitabine
Female3
Male16
08

Study locations

1 site
  • Bucuresti, 022328, Romania
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Oct 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2008
First posted
Jun 19, 2008
Start
Aug 2008
Primary completionActual
Oct 2010
CompletionActual
Dec 2010
Results first posted
May 19, 2016
Last update
Jun 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00701558
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 19, 2008
Start date
Aug 2008
Primary completion
Oct 2010
Completion
Dec 2010
Results posted
May 19, 2016
Last update
Jun 24, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Erlotinib · Gemcitabine

Start the discussion